Drug Search Results

NIM-1324

Alternative Names: NIM-1324, NIM1324, NIM 1324, labp-104, labp 104, labp104
Latest Update: 2024-10-07
Latest Update Note: News Article

Product Description

A novel, oral, systemically delivered LANCL2 agonist,for the treatment of rheumatoid arthritis (Sourced from: https://ir.landosbiopharma.com/news-releases/news-release-details/landos-biopharma-announces-fda-clearance-its-ind-labp-104-0)

Mechanisms of Action: LANCL2 Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: NImmune Biopharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NIM-1324

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Lupus Erythematosus, Systemic

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
LABP-104-1a	P1	Completed	Lupus Erythematosus, Systemic	2022-04-28

Recent News Events

Date	Type	Title
10/07/2024	News Article	The NIMML Institute and NImmune Biopharma Announce Publication of New Mechanistic Insights on the Immunometabolic Control of Systemic Lupus Erythematosus in the Journal of Immunology
04/10/2024	News Article	NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists
03/25/2024	News Article	NIMML Institute's TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie's Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13
11/14/2023	News Article	NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions